Evidence map›Paper›PMID 34618307›Full record

ArticleImmunologic research2022

Primary antibody deficiencies in Turkey: molecular and clinical aspects.

Sinem Firtina, Yuk Yin Ng, Ozden H Ng, Ayca Kiykim, Esra Yucel Ozek, Manolya Kara, Elif Aydiner, Serdar Nepesov, Yildiz Camcioglu, Esra H Sayar and 11 more

Erratum issuedOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Sinem Firtina *Istanbul University Graduate School of Health Sciences, Istanbul, Turkey.ORCID 0000-0002-3370-8545
Yuk Yin Ng *Department of Genetics and Bioengineering, Istanbul Bilgi University, Istanbul, Turkey.
Ozden H NgDepartment of Medical Biology, Acibadem School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
Ayca KiykimDepartment of Infectious Diseases and Clinical Immunology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
Esra Yucel OzekDepartment of Clinical Immunology, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey.
Manolya KaraIstinye University Faculty of Medicine, VM MedicalPark Pendik Hospital, Pediatric Infectious Diseases Clinic, Istanbul, Turkey.
Elif AydinerDepartment of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.
Serdar NepesovDepartment of Pediatric Allergy Immunology, Medipol University, Istanbul, Turkey.
Yildiz CamciogluDepartment of Infectious Diseases and Clinical Immunology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
Esra H SayarDepartment of Pediatric Immunology and Allergy, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey.
Ezgi Yalcin GungorenDepartment of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.
Ismail ReisliDepartment of Pediatric Immunology and Allergy, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey.
Selda H TorunDepartment of Clinical Immunology, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey.
Sule HaskologluDepartment of Pediatric Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.
Tuba CogurluDepartment of Pediatric Immunology and Allergy, Kocaeli University, Kocaeli, Turkey.
Aysenur KayaIstinye University Faculty of Medicine, VM MedicalPark Pendik Hospital, Pediatric Infectious Diseases Clinic, Istanbul, Turkey.
Sukru CekicDepartment of Pediatric Immunology, Uludag University School of Medicine, Bursa, Turkey.
Safa BarisDepartment of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.
Ugur OzbekDepartment of Medical Genetics, Acibadem School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
Ahmet OzenDepartment of Pediatric Allergy and Immunology, Marmara University, Istanbul, Turkey.
Muge SayitogluIstanbul University Graduate School of Health Sciences, Istanbul, Turkey. mugeay@istanbul.edu.tr.ORCID 0000-0002-8648-213X
Istanbul University · TRMarmara University · TRIstinye University · TRKent Hastanesi · TRNecmettin Erbakan University · TRAnkara University · TRBursa Uludağ Üni̇versi̇tesi̇ · TRIstanbul Bilgi University · TRIstanbul Medipol University · TRKocaeli Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary antibody deficiencies (PAD) are the most common subtype of primary immunodeficiencies, characterized by increased susceptibility to infections and autoimmunity, allergy, or malignancy predisposition. PAD syndromes comprise of immune system genes highlighted the key role of B cell activation, proliferation, migration, somatic hypermutation, or isotype switching have a wide spectrum from agammaglobulinemia to selective Ig deficiency. In this study, we describe the molecular and the clinical aspects of fifty-two PAD patients. The most common symptoms of our cohort were upper and lower respiratory infections, bronchiectasis, diarrhea, and recurrent fever. Almost all patients (98%) had at least one of the symptoms like autoimmunity, lymphoproliferation, allergy, or gastrointestinal disease. A custom-made next-generation sequencing (NGS) panel, which contains 24 genes, was designed to identify well-known disease-causing variants in our cohort. We identified eight variants (15.4%) among 52 PAD patients. The variants mapped to BTK (n = 4), CD40L (n = 1), ICOS (n = 1), IGHM (n = 1), and TCF3 (n = 1) genes. Three novel variants were described in the BTK (p.G414W), ICOS (p.G60*), and IGHM (p.S19*) genes. We performed Sanger sequencing to validate pathogenic variants and check for allelic segregation in the family. Targeted NGS panel sequencing can be beneficial as a suitable diagnostic modality for diagnosing well-known monogenic PAD diseases (only 2-10% of PADs); however, screening only the coding regions of the genome may not be adequately powered to solve the pathogenesis of PAD in all cases. Deciphering the regulatory regions of the genome and better understanding the epigenetic modifications will elucidate the molecular basis of complex PADs.

Indexed as

AgammaglobulinemiaHypersensitivityPrimary Immunodeficiency DiseasesHigh-Throughput Nucleotide SequencingHumansTurkeyCommon variable immune deficiencyPrimary antibody deficienciesTargeted next-generation sequencing

Identifiers

PMID34618307
OpenAlexW3202383752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.